ElizabethAnneFlodinDO

PubMed

• Application of a Flow-Based Hollow-Fiber Co-Culture System to Study Cellular Influences under Hyperglycemic Conditions.
  Ebrahim, A. S.,Carion, T. W.,Strand, E.,Young, L. A.,Shi, H.,Berger, E. A.> ;Sci Rep. 2019 Mar 09
• VIP modulates the ALX/FPR2 receptor axis toward inflammation resolution in a mouse model of bacterial keratitis.
  Carion, T. W.,Kracht, D.,Strand, E.,David, E.,McWhirter, C.,Ebrahim, A. S.,Berger, E. A.> ;Prostaglandins Other Lipid Mediat.. 2018 Dec 12
• HASH(0x1dd6648)
  Carion, T. W.,Ebrahim, A. S.,Kracht, D.,Agrawal, A.,Strand, E.,Kaddurah, O.,McWhirter, C. R.,Sosne, G.,Berger, E. A.> ;Cells. 2018 Sep 23
• Immunoregulatory role of 15-lipoxygenase in the pathogenesis of bacterial keratitis.
  Carion, T. W.,Greenwood, M.,Ebrahim, A. S.,Jerome, A.,Suvas, S.,Gronert, K.,Berger, E. A.> ;FASEB J.. 2018 Jun 20
• β-Adrenergic receptor agonist, compound 49b, inhibits TLR4 signaling pathway in diabetic retina.
  Berger EA, Carion TW, Jiang Y, Liu L, Chahine A, Walker RJ, Steinle JJ> ;Immunol. Cell Biol.. 2016-08-01
• Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis.
  Muraleedharan, C. K.,McClellan, S. A.,Barrett, R. P.,Li, C.,Montenegro, D.,Carion, T.,Berger, E.,Hazlett, L. D.,Xu, S.> ;Invest. Ophthalmol. Vis. Sci.. 2016 Apr 02
• VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.
  Shi H, Carion TW, Jiang Y, Steinle JJ, Berger EA> ;Prostaglandins Other Lipid Mediat.. 2016-03-01
• Efficacy of VIP as Treatment for Bacteria-Induced Keratitis Against Multiple Pseudomonas aeruginosa Strains.
  Carion, T. W.,McWhirter, C. R.,Grewal, D. K.,Berger, E. A.> ;Invest. Ophthalmol. Vis. Sci.. 2015 Oct 30
• 8 citations
  Universal versus risk factor-targeted early inpatient postpartum depression screening
  Elizabeth A. Berger, Amy Wu, Elizabeth A Smulian, Joanne N. Quiñones, Sandra Curet, Rory L Marraccini, John C. Smulian> ;The Journal of Maternal-Fetal & Neonatal Medicine. 2015 Jun 8
• 34 citations
  A comparison of quality outcome measures in patients having a hysterectomy for benign disease: robotic vs. non-robotic approaches.
  Martin A. Martino, Elizabeth A. Berger, Jeffrey T. McFetridge, Jocelyn Shubella, Gabrielle Gosciniak, Taylor Wejkszner, Gregory F. Kainz, Jeremy Patriarco, M Bijoy Tho...> ;Journal of Minimally Invasive Gynecology. 2014 May 1
• HIF-1α Is Essential for Effective PMN Bacterial Killing, Antimicrobial Peptide Production and Apoptosis in Pseudomonas aeruginosa Keratitis.
  Berger, E. A.,McClellan, S. A.,Vistisen, K. S.,Hazlett, L. D.> ;PLoS Pathog.. 2013 Jul
• Mammalian Target of Rapamycin Regulates IL-10 and Resistance to Pseudomonas aeruginosa Corneal Infection.
  Foldenauer, M. E.,McClellan, S. A.,Berger, E. A.,Hazlett, L. D.> ;J. Immunol.. 2013 Jun 1
• Effects of VIP on corneal reconstitution and homeostasis following Pseudomonas aeruginosa induced keratitis.
  Berger, E. A.,Vistisen, K. S.,Barrett, R. P.,Hazlett, L. D.> ;Invest. Ophthalmol. Vis. Sci.. 2012 Oct 06
• VIP and growth factors in the infected cornea.
  Jiang, X., McClellan, S.A., Barrett, R.P., Berger, E.A., Zhang, Y., Hazlett, L.D.> ;Invest Ophthalmol Vis Sci. 2011 Aug
• Testican-1 promotes resistance against P. aeruginosa-induced keratitis through regulation of MMP-2 expression and activation.
  Berger, E.A., McClellan, S.A., Barrett, R.P., Hazlett, L.D.> ;Invest Ophthalmol Vis Sci. 2011 Jul
• VIP promotes resistance in the Pseudomonas aeruginosa-infected cornea by modulating adhesion molecule expression.
  Berger, E.A., McClellan, S.A., Barrett, R.P., Hazlett, L.D.> ;Invest Ophthalmol Vis Sci. 2010 Nov
• Join now to see all